Market research
 

THET PAING SOE’S operating culture alongside talented, well-trained and experienced personnel, our sales team has steered its course through vast network of distribution pipelines throughout Myanmar.



On a regular basis, our professional sales representatives visit our customers to fulfill their needs not only by collecting orders but also by sharing useful and updated information as well.

Regulatory Affairs
• Regulatory Affairs services
• Updated laws and health regulations
• PV reports


We can handle and provide Regulatory Affairs services to our valued partners who are in need. In addition, updated laws and health regulations and Pharmacovigilance reports could also be provided by our Regulatory Affairs Department.

 

 
 
Marketing Management

THET PAING SOE has its core marketing team with enough knowledge & skills through which it can provide all clinicians with complete, accurate, comprehensive and impartial information regarding pharmaceuticals.

Market research
 


As part of the requirements of marketing management, we conduct market research in order to make sure understanding of the market situation and consumer’s behavior.
Nationwide Distribution
 


We have our own wholesales & retail sales outlets in Yangon & Mandalay. Through these outlets as well as our Van Sales, we offer a nationwide distribution designed to cover important parts of the country.

We provide the efficient delivery service within 24 hours after receiving an order and also serve an urgent delivery in order to fulfill customers’ special needs.

Logistics
  • • Application for Import License
  • • Customs clearance
  • • Payment remittance
All importation procedures: Application of IL at the Ministry of Commerce, Customs clearance on the product arrival and payment remittance to the related banks are performed by our Logistics Team.
 

AVAXIM 160 U

san-3-2

CONTENTS

Inactivated hepatitis A vaccine, adsorbed.

PRESENTATION

Prefilled syringe 0.5 mL (single-dose susp for inj, fitted with an elastomer plunger-stopper) x 1's.

DESCRIPTION

Each 0.5-mL dose contains hepatitis A virus GBM strain* (inactivated**), 160 U***.
*Cultured on MRC-5 human diploid cells.
**Absorbed on aluminium hydroxide (quantity corresponding to 0.3 mg of aluminium).
***Antigen units measured using an in-house manufacturer's reference.
It also contains the following ingredients: Phenoxyethanol, formaldehyde, Hanks 199 Medium (containing a complex mixture of amino acids, mineral salts, vitamins, hydrochloric acid or sodium hydroxide for pH adjustment and water for injection).

INDICATIONS

Prevention of infection caused by hepatitis A virus in adolescents from 16 years and in adults.
Avaxim 160 U does not protect against infection caused by other types of hepatitis virus or any other known liver pathogens.
Avaxim 160 U should be administered in accordance with official recommendations.

DOSAGE & ADMINISTRATION

Recommended Dosage: 0.5 mL.
The initial protection is obtained after 1 single injection.
In order to obtain long-term protection, a second dose (booster) should be administered preferably between 6 and 12 months after the first vaccination and until 36 months after the first vaccination.
Avamix 160 U may also be administered as a booster dose of the Hepatitis A vaccination in subjects who have received the first injection with the combined typhoid fever (Vi purified polysaccharide) and hepatitis A (inactivated) vaccine between 6 and 36 months earlier.
Administration: It is recommended to administer Avaxim 160 U by the IM route to minimize local reactions. The recommended injection site is the deltoid muscle (upper arm muscle).
Do not inject by the intravascular route: Make sure that the needle does not penetrate a blood vessel.
Avaxim 160 U is not to be injected into the buttocks (due to the presence of varying amounts of adipose tissue), nor administered intradermally, since these routes of administration may induce a weaker immune response.
In exceptional cases, Avaxim 160 U may be administered by the SC route in patients suffering from thrombocytopenia or in patients at risk of hemorrhage.
Avaxim 160 U must not be mixed with other vaccines in the same syringe.

CONTRAINDICATIONS

Hypersensitivity to any of the components of Avaxim 160 U or following a previous injection.
Vaccination should be postponed in case of fever, acute disease or progressive chronic disease.

PRECAUTIONS

Do not inject by intravascular route: Make sure that the needle does not enter a blood vessel. Avaxim 160 U is not to be injected into the buttocks (due to the presence of varying amounts of adipose tissue), nor administered intradermally, since these routes of administration may induce a weaker immune response; immunosuppressant treatment or a state of immune deficiency may lead to a diminished immune response to the vaccine.
If the vaccine is administered during the incubation period of the disease, it may have no effect on the development of hepatitis A.
The use of Avaxim 160 U in subjects with liver disease and with hypersensitivity to neomycin (each dose of vaccine contains trace amounts of neomycin) should be considered with caution.
Effects on the Ability to Drive or Operate Machinery: Avaxim 160 U is unlikely to produce an effect on the ability to drive and use machines.
Use in pregnancy & lactation: Avaxim 160 U should be used during pregnancy on medical advice only.
The use of Avaxim 160 U is possible during lactation.

SIDE EFFECTS

Local pain sometimes associated with redness. The appearance of a nodule at the injection site has been observed in very rare cases.
Moderate fever, fatigue, headache, muscle or joint pain and GI disorder have been the most commonly observed side effects.
A mild reversible elevation in liver enzymes (transaminases) has been observed on rare occasions.
Exceptional skin reactions eg, pruritus, rash (cutaneous eruption) or urticaria have been reported.
Inform the physician if these symptoms persist or worsen.

INTERACTIONS

Avaxim 160 U may be administered simultaneously with immunoglobulins provided 2 different injection sites are used.
Since Avaxim 160 U is inactivated, administration with other inactivated vaccines at a different injection site does not generally result in any interaction.
Avaxim 160 U can be administered simultaneously but at separate sites, as a recombinant hepatitis B vaccine or a polysaccharide typhoid vaccine.
Avaxim 160 U can also be administered with a live yellow fever vaccine, using a different injection site.
Avaxim 160 U can be used as a booster dose in subjects who have received primary vaccination with another inactivated hepatitis A vaccine.
Inform the doctor or pharmacist if the patient is taking or have recently taken any other medicines, even those obtained without a prescription.

CAUTIONS FOR USAGE

Instructions for Use and Handling: Shake before injection, until a homogenous suspension is obtained.
For the syringes without attached needles, the separate needle should be fitted firmly to the syringe, rotating it by one quarter turn.
Any unused product or waste material should be disposed of in accordance with local requirements.

STORAGE

Store in a refrigerator (between 2°C and 8°C). Do not freeze.
Shelf-Life: 3 years.